Does PEMIGATINIB Cause Cholangiocarcinoma? 44 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 44 reports of Cholangiocarcinoma have been filed in association with PEMIGATINIB (PEMAZYRE). This represents 6.2% of all adverse event reports for PEMIGATINIB.
44
Reports of Cholangiocarcinoma with PEMIGATINIB
6.2%
of all PEMIGATINIB reports
19
Deaths
4
Hospitalizations
How Dangerous Is Cholangiocarcinoma From PEMIGATINIB?
Of the 44 reports, 19 (43.2%) resulted in death, 4 (9.1%) required hospitalization, and 1 (2.3%) were considered life-threatening.
Is Cholangiocarcinoma Listed in the Official Label?
Yes, Cholangiocarcinoma is listed as a known adverse reaction in the official FDA drug label for PEMIGATINIB.
What Other Side Effects Does PEMIGATINIB Cause?
Off label use (114)
Disease progression (103)
Death (76)
Fatigue (72)
Alopecia (53)
Hyperphosphataemia (46)
Diarrhoea (42)
Constipation (37)
Drug ineffective (37)
Hospitalisation (35)
What Other Drugs Cause Cholangiocarcinoma?
RANITIDINE (100)
ADALIMUMAB (62)
TACROLIMUS (56)
METHOTREXATE (55)
INFLIXIMAB (54)
LENALIDOMIDE (49)
PREDNISONE (48)
MYCOPHENOLATE MOFETIL (45)
CYCLOPHOSPHAMIDE (42)
DEXAMETHASONE (42)
Which PEMIGATINIB Alternatives Have Lower Cholangiocarcinoma Risk?
PEMIGATINIB vs PENICILLAMINE
PEMIGATINIB vs PENICILLIN
PEMIGATINIB vs PENICILLIN G
PEMIGATINIB vs PENICILLIN G BENZATHINE
PEMIGATINIB vs PENICILLIN G PROCAINE